Skip to main content

Fiscal Wizard · Single-issue tearsheet

MREO / Jun 21, 2026 Run #7487

MREO

Mereo BioPharma Group plc

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.

Composite verdict

F 9.8 / 100
Bearish setup · Reversal 8 drivers · 4 gates blocking
  • Coppock Curve
  • Vortex Signal
  • Pin Bar
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 440th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: downtrend
Bull 0%Evidence: High · 17 signals100% Bear
Momentum Bearish 8Mean-reversion Neutral 49

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -70%

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

18.8 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Gross Margin 75
Margin of Safety 0
P/B 75
Greenblatt EY 0
EPS Growth (YoY) 67
Free Cash Flow Yield 0

Technicals Bearish

0.7 / 100

Bearish setup leads (Coppock Curve, Vortex Signal, Pin Bar); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Coppock Curve 13
Vortex Signal 15
Accumulation/Distribution Line 16

Risk Gates

4 blocking 7 caution

4 guards active, 23 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for MREO.